Daiichi Sankyo Presents P-II Trial (HERTHENA-Lung01) Results of Patritumab Deruxtecan for EGFR-Mutated Metastatic NSCLC at WCLC 2023
Shots:
- The P-II trial evaluating patritumab deruxtecan (5.6mg/kg) in a ratio (1:1) in patients with EGFR-mutated LA or metastatic NSCLC following disease progression with an EGFR TKI and Pt-based CT in Asia, EU, North America & Oceania
- The results showed clinically meaningful & durable responses, confirmed ORR (29.8%), 1 CR, PR (66) & 99 cases of SD, m-DoR of 6.4mos. & DCR (73.8%), m-PFS was 5.5mos. & m-OS was 11.9mos. Efficacy outcomes were consistent across subgroups incl. a subset of 209 patients prior treated with a third-generation EGFR TKI and Pt-based CT
- The safety profile was consistent with prior clinical trials with a low rate (7.1%) of treatment discontinuation due to TEAEs, grade ≥3 (64.9%). The results were published in the Journal of Clinical Oncology
Ref: Businesswire | Image: Daiichi Sankyo
Related news:- Daiichi Sankyo Initiates P-II Study of Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
